Skip to main content
Log in

In Vitro pharmacodynamics of CKD-602 in HT-29 cells

  • Research Articles
  • Articles
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

An Erratum to this article was published on 01 December 2002

Abstract

CKD-602 (7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin) is a recently-developed synthetic camptothecin analogue and currently under clinical development by Chong Kun Dang Pharm (Seoul, Korea). CKD-602 showed potent topoisomerase inhibitory activityin vitro and broad antitumor activity against various human tumor cells in vitro and in vivo in animal models. This study describes the pharmacodynamics of the immediate and delayed cytotoxicity induced by CKD-602 in a human colorectal adenocarcinoma cell line, HT-29, and its intracellular drug accumulation by HPLC. The present study was designed to address whether the higher activity of CKD-602 with prolonged exposure is due to delayed exhibition of cytotoxicity and/or an accumulation of antiproliferative effect on continuous drug exposure. The drug uptake study was performed to determine whether the delayed cytotoxicity is due to a slow drug accumulation in cells. CKD-602 produced a cytotoxicity that was exhibited immediately after treatment (immediate effect) and after treatment had been terminated (delayed effect). Both the immediate and delayed effects of CKD-602 showed a time dependent decrease in IC50 values. Drug uptake was biphasic and the second equilibrium level was obtained as early as at 24hr, indicating that the cumulative and delayed antitumor effects of CKD-602 were not due to slow drug uptake. On the other hand, CKD-602 treatment was sufficient to induce delayed cytotoxicity after 4hr, however, longer treatment (>24hr) enhanced its cytotoxicity due to the intracellular accumulation of the drug, which requires 24hr to reach maximum equilibrium concentration. In addition, CnxT=h analysis (n=0.481) indicated that increased exposure times may contribute more to the overall antitumor activity of CKD-602 than drug concentration. Additional studies to determine the details of the intracellular uptake kinetics (e.g., concentration dependency and retention studies) are needed in order to identify the optimal treatment schedules for the successful clinical development of CKD-602.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Au, J.L-S., Li, D., Gan, Y., Gao, X., Johnson, A.L., Johston, J., Millenbaugh, N.J., Jang, S.H., Kuh, H., Chen, C. and Wientjes, M.G., Pharmacodynamics of immediate and delayed effects of paclitaxel: Role of slow apoptosis and intracellular drug retention.Cancer Res., 58, 2141–2148 1998.

    PubMed  CAS  Google Scholar 

  • Beijnen, J.H., Smiti, B.R., Keijer, W.J., Van Gijn, R., Ten Bokkel Huinink, W.W., Vlasveli, L. T., Rodenhuis, S. and Underberg, W. J. M., High-performance liquid chromatographic analysis of the new antitumor drug SK&F 104864-A(NSC 609699) in plasma.J. Pharm. & Biom. Anal., 8, 789–794 (1990).

    Article  CAS  Google Scholar 

  • Creemers, G.J., Lund, B. and Verweij, J., Topoisomerase I inhibitors: topotecan and irenotecan.Cancer Treat. Rev., 20, 73–96 1994.

    Article  PubMed  CAS  Google Scholar 

  • Gerrits, C.J., Schellens, J.H., Burris, H., Eckardt, J.R., Planting, A.S., van Beurder Burg, A.M., Rodriguez, G.I. Loos, W.J. van Beurden V. and Verwei, J., A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan.Clin. Cancer Res., 5, 69–75 1999.

    PubMed  CAS  Google Scholar 

  • Gieschke R., and Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.Eur. J. Drug Metab. Pharmacokinet., 25, 49–58 (2000).

    PubMed  CAS  Google Scholar 

  • Jew S.S, Kim M.G, Kim H.J, Rho E.Y, Park H.G, Kim J.K, Han H.J, and Lee H. Synthesis andin vitro cytotoxicity of C(20)(RS)-camptothecin analogues modified at both B (or A) and E ring.Bioorg. Med. Chem. Lett., 8, 1797–1800 (1998).

    Article  PubMed  CAS  Google Scholar 

  • Jung L.L, and Zamboni W.C. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?Drug Resist. Updat., 4, 273–288 (2001).

    Article  PubMed  CAS  Google Scholar 

  • Kalns, J.E., Millenbaugh, N.J., Wientjes, M.G. and Au, J.L-S. Design and analysis ofin vitro antitumor pharmacodynamic studies.Cancer Res., 55, 5315–5322 (1995).

    PubMed  CAS  Google Scholar 

  • Kohn, K.W., and Pommier, Y. Molecular and biological determinants of the cytotoxic actions of camptothecins. Perspective for the development of new topoisomerase I inhibitors.Ann. N. Y. Acad. Sci., 922, 11–26 (2000).

    PubMed  CAS  Google Scholar 

  • Kuh, H. J., Jang, S.H., Wientjes, M.G., Weaver, J.R. and Au, J.L-S. Computational model of intracellular pharmacokinetics of paclitaxel.J. Pharmacol. & Exp. Ther., 293, 761–770 (2000).

    CAS  Google Scholar 

  • Kuh, H. J., Jang, S.H., Wientjes, M.G., Weaver, J.R. and Au, J.L-S. Determinants of paclitaxel penetration and accumulation in human solid tumor.J. Pharmacol. & Exp. Ther., 871-880, 290 (1999).

    Google Scholar 

  • Lee, J.H., Lee, J.M., Kim, J.K., Ahn, S.K., Lee, S.J., Kim, M.Y, Jew, S.S., Park, J.G., and Hong, C.I., Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.Arch. Pharm. Res., 21, 581–590 1998.

    Article  PubMed  CAS  Google Scholar 

  • Lee, J.H., Lee, J.M., Lim, K.H., Kim, J.K., Ahn, S.K., Bang, Y.J., and Hong, C.I., Preclinical and phase I clinical studies with Ckd-602, a novel camptothecin derivative.Ann. N. Y. Acad. Sci., 922, 324–325 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Levasseur, L.M., Slocum, H.K., Rustum, Y.M., Greco, W.R., Modeling of the time-dependency ofin vitro drug cytotoxicity and resistance.Cancer Res., 58, 5749–5761 1998.

    PubMed  CAS  Google Scholar 

  • Li, M.L, Horn, L., Firby, P.S., and Moore, M.J., Pharmacological determinants of 9-aminocamptothecin cytotoxicity.Clin. CancerRes., 7, 168–174 2001.

    CAS  Google Scholar 

  • Meibohm, B. and Derendorf, H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.Int. J. Clin. Pharmacol. & Ther., 35, 401–413 (1997).

    CAS  Google Scholar 

  • Oguma, T., Ohshima, Y. and Nakaoka, M. Sensitive highperformance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection,J. Chromatogr. B. Biomed. Sci. Appl., 740, 237–245 (2000).

    Article  PubMed  CAS  Google Scholar 

  • Skipper, H.E., The effects of chemotherapy on the kinetics of leukemic cell.CancerRes., 25, 1544–1550 1965.

    CAS  Google Scholar 

  • Slichenmyer, W.J., Rowinsky, E.K., Donehower, R.C., and Kaufmann, S.H., The current status of camptothecin analogues as antitumor agents.J. Natl. Cancer. Inst, 85, 271–291 (1993).

    Article  PubMed  CAS  Google Scholar 

  • Takimoto, C.H., Wright, J., and Arbuck, S.G., Clinical applications of the camptothecins.Biochim. Biophys. Acta, 1400, 107–119 1998.

    PubMed  CAS  Google Scholar 

  • van den Bongard, H.J., Mathot, R.A., Beijnen, J.H., and Schellens, J.H., Pharmacokinetically guided administration of chemotherapeutic agents.Clin. Pharmacokinet., 39, 345–367 2000.

    Article  PubMed  Google Scholar 

  • Vigano, L., Locatelli, A., Grasselli, G., and Gianni, L., Drug interactions of paclitaxel and docetaxel and their relevance for the design of combination therapy. Invest.New Drugs, 19, 179–196 2001.

    Article  CAS  Google Scholar 

  • Wall, M.E., Wani, M.C., Cook, C.E., and Palmer, K.H. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata.J. Am. Chem. Soc., 88, 3888–3890 (1966).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hyo-Jeong Kuh.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF02977025.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, IS., Ahn, M.R., Suh, S.K. et al. In Vitro pharmacodynamics of CKD-602 in HT-29 cells. Arch Pharm Res 25, 718–723 (2002). https://doi.org/10.1007/BF02976950

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02976950

Key words

Navigation